Adrenaline: 3 agencies, 2003–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 22.8 years separate the first record, 15 Oct 2003 at HAS (France), from the most recent, 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2026, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for adrenaline at all.
Not every gap is a refusal: for adrenaline, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 2 of 23 records date from 2023 or later.
4 distinct indication wordings are recorded for adrenaline by the agencies that label one in English (AWMSG and PBAC).
6 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess adrenaline, on 15 Oct 2003; PBAC (Australia) did not open a file until 2016 — an unusually long tail of 12.8 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 14 years in total.
3 of the 3 agencies here assessed adrenaline more than once, HAS (France) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed adrenaline.
The full ledger for adrenaline reads 16 recommended, 2 not assessed, 2 other and 1 withdrawn, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Acute allergic reaction with anaphylaxis | Recommended | source |
| HAS (France) | 22 Apr 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 24 Jan 2018 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 11 Feb 2014 | Emergency treatment of severe acute allergic reactions (anaphylaxis) triggered by allergens in foods, medicines, insect … | outside AWMSG criteria | source |
| HAS (France) | 8 Jan 2014 | Listing (Transparency Committee) | ASMR V | source |
18 further decisions for adrenaline, across 3 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- phenylephrine — same ATC class C01C — Cardiac therapy
- angiotensin ii — same ATC class C01C — Cardiac therapy
- midodrine — same ATC class C01C — Cardiac therapy
- teriparatide — also decided by HAS in 2020Q2
- tobramycin — also decided by HAS in 2020Q2
- rituximab — also decided by HAS in 2020Q2
Coverage: 23 decisions for adrenaline from 3 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class C01C — Cardiac therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.